Skip to main content
SpringerLink
Log in

HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations

  • Chapter
  • First Online:
Hereditary Gastric and Breast Cancer Syndrome

  • 248 Accesses

Abstract

The role of human epidermal growth factor receptor-2 (HER2) is involved in epithelial cells growth and differentiation and has been widely studied in a plethora of cancers. HER2 alterations have been known to drive tumor cell proliferation, migration and reduce apoptosis. Tumor expression of HER2 marker has prognostic and predictive significance in breast and gastroesophageal cancers. These two cancer types may arise as constituents of hereditary diffuse gastric cancer syndrome (HDGS), which is linked to E-cadherin coding CDH1 gene alterations. Precisely, HDGS features a high prevalence of diffuse gastric and lobular breast cancers. HER2 alterations may simultaneously occur with CDH1 mutations; however, the role of HER2 overexpression in these patients and two biomarkers’ relationship is not fully understood.

In this chapter, we sought to provide a comprehensive overview of the biological role of HER2 biomarker and current testing guidelines in breast and gastric cancer, in association with genetic CDH1 alterations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG et al (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20(1):120–129

    Article  CAS  PubMed  Google Scholar 

  2. Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748

    Article  PubMed  PubMed Central  Google Scholar 

  3. Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M et al (2021) Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7(1):137

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G et al (2022) HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 9:834651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. He L, Araj E, Peng Y (2021) HER2 positive and HER2 negative classical type invasive lobular carcinomas: comparison of clinicopathologic features. Curr Oncol 28(3):1608

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fusco N, Bosari S (2016) HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists. World J Gastroenterol 22(35):7926–7937

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Aoki M, Iwasa S, Boku N (2021) Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 24(3):567–576

    Article  CAS  PubMed  Google Scholar 

  8. Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D et al (2021) Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell 39(8):1099–114.e8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Arteaga CL, Engelman JA (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jeong J, Kim W, Kim LK, VanHouten J, Wysolmerski JJ (2017) HER2 signaling regulates HER2 localization and membrane retention. PLoS One 12(4):e0174849

    Article  PubMed  PubMed Central  Google Scholar 

  11. Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48

    Article  CAS  PubMed  Google Scholar 

  12. Pollock NI, Grandis JR (2015) HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 21(3):526–533

    Article  CAS  PubMed  Google Scholar 

  13. Criscitiello C, Marra A, Curigliano G (2021) PIK3CA mutation assessment in HR+/HER2− metastatic breast cancer: overview for oncology clinical practice. J Mol Pathol 2(1)

    Google Scholar 

  14. Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S et al (2021) PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front Oncol 11

    Google Scholar 

  15. Najjar S, Allison KH (2022) Updates on breast biomarkers. Virchows Arch 480(1):163–176

    Article  CAS  PubMed  Google Scholar 

  16. Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123–135

    Article  PubMed  Google Scholar 

  17. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    Article  CAS  PubMed  Google Scholar 

  18. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51(3):1034–1038

    CAS  PubMed  Google Scholar 

  19. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J et al (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85(9):1894–1902

    Article  CAS  PubMed  Google Scholar 

  20. Liu Y, Chen L, Jiang D, Luan L, Huang J, Hou Y et al (2021) HER2 promotes epithelial-mesenchymal transition through regulating osteopontin in gastric cancer. Pathol – Res Pract 227:153643

    Article  CAS  PubMed  Google Scholar 

  21. Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G et al (2012) Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 61(5):769–776

    Article  PubMed  Google Scholar 

  22. Falk GW (2002) Barrett’s esophagus. Gastroenterology 122(6):1569–1591

    Article  PubMed  Google Scholar 

  23. Nagaraja V, Shaw N, Morey AL, Cox MR, Eslick GD (2016) HER2 expression in oesophageal carcinoma and Barrett’s oesophagus associated adenocarcinoma: an Australian study. Eur J Surg Oncol 42(1):140–148

    Article  CAS  PubMed  Google Scholar 

  24. Arcidiacono D, Antonello A, Fassan M, Nucci D, Morbin T, Agostini M et al (2017) Insulin promotes HER2 signaling activation during Barrett’s esophagus carcinogenesis. Dig Liver Dis 49(6):630–638

    Article  CAS  PubMed  Google Scholar 

  25. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA et al (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18(2):546–554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE et al (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 30(32):3932–3938

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL (2012) Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 29(2):933–940

    Article  CAS  PubMed  Google Scholar 

  28. Gowryshankar A, Nagaraja V, Eslick GD (2014) HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol 5(1):25–35

    PubMed  PubMed Central  Google Scholar 

  29. Hamilton E, Shastry M, Shiller SM, Ren R (2021) Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev 100:102286

    Article  CAS  PubMed  Google Scholar 

  30. Viale G, Fusco N (2021) Pathology after neoadjuvant treatment – how to assess residual disease. Breast 56:S13

    Article  Google Scholar 

  31. Ahn S, Woo JW, Lee K, Park SY (2020) HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 54(1):34–44

    Article  PubMed  Google Scholar 

  32. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M (2018) HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update summary. J Oncol Pract 14(7):437–441

    Article  PubMed  Google Scholar 

  33. WHO Classification of Tumours Editorial Board (2019) WHO Classification of Breast Tumours: WHO Classification of Tumours, vol 2. World Health Organization

    Google Scholar 

  34. Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG (2020) Applying the new guidelines of HER2 testing in breast cancer. Curr Oncol Rep 22(5):51

    Article  PubMed  Google Scholar 

  35. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38(17):1951–1962

    Article  CAS  PubMed  Google Scholar 

  36. Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P et al (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35–43

    Article  CAS  PubMed  Google Scholar 

  37. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F et al (2013) HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol 26(6):816–824

    Article  CAS  PubMed  Google Scholar 

  38. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V et al (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124–1135

    Article  CAS  PubMed  Google Scholar 

  39. MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG et al (2020) New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified. J Cancer Res Clin Oncol 146(3):605–619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG (2022) HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol 35:1075

    Article  CAS  PubMed  Google Scholar 

  41. Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E et al (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66(6):313–324

    Article  PubMed  Google Scholar 

  42. Jensen SG, Thomas PE, Christensen IJ, Balslev E, Hansen A, Høgdall E (2020) Evaluation of analytical accuracy of HER2 status in patients with breast cancer: comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS 128(11):573–582

    Article  CAS  PubMed  Google Scholar 

  43. Gordian-Arroyo AM, Zynger DL, Tozbikian GH (2019) Impact of the 2018 ASCO/CAP HER2 guideline focused update. Am J Clin Pathol 152(1):17–26

    Article  CAS  PubMed  Google Scholar 

  44. Abrahao-Machado LF, Scapulatempo-Neto C (2016) HER2 testing in gastric cancer: an update. World J Gastroenterol 22(19):4619–4625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Setia N, Ahn S, Han HS, Park DY, Lauwers GY (2019) Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma. Hum Pathol 94:64–70

    Article  CAS  PubMed  Google Scholar 

  46. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446–464

    Article  CAS  PubMed  Google Scholar 

  47. Satoh T, Bang YJ, Gotovkin EA, Hamamoto Y, Kang YK, Moiseyenko VM et al (2014) Quality of life in the trastuzumab for gastric cancer trial. Oncologist 19(7):712–719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H et al (2015) Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 18(4):691–697

    Article  CAS  PubMed  Google Scholar 

  49. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol 23(10):2656–2662

    Article  CAS  PubMed  Google Scholar 

  50. Van Cutsem E, Kang YK, Shen L, Lordick F, Ohtsu A, Satoh T et al (2009) 7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the phase III ToGA trial. Eur J Cancer Suppl 7(3):7

    Article  Google Scholar 

  51. Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Mouhieddine TH et al (2022) CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. Br J Cancer 126(5):797–803

    Article  CAS  PubMed  Google Scholar 

  52. Massari G, Magnoni F, Favia G, Peradze N, Veronesi P, La Vecchia C et al (2021) Frequency of CDH1 germline mutations in non-gastric cancers. Cancers (Basel) 13(10)

    Google Scholar 

  53. Zhao H, Hu H, Chen B, Xu W, Zhao J, Huang C et al (2021) Overview on the role of E-cadherin in gastric cancer: dysregulation and clinical implications. Front Mol Biosci 8:689139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Shenoy S (2019) CDH1 (E-cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management. Cancer Manag Res 11:10477–10486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Han T, Jiang S, Zheng H, Yin Q, Xie M, Little MR et al (2019) Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. Nat Commun 10(1):3716

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H et al (2015) Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1(1):23–32

    Article  PubMed  Google Scholar 

  57. Schrader KA, Masciari S, Boyd N, Wiyrick S, Kaurah P, Senz J et al (2008) Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer 7(1):73–82

    Article  PubMed  Google Scholar 

  58. (2021) Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med 384(5):428–439

    Google Scholar 

  59. Luo W, Fedda F, Lynch P, Tan D (2018) CDH1 gene and Hereditary diffuse gastric cancer syndrome: molecular and histological alterations and implications for diagnosis and treatment. Front Pharmacol 9:1421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Hu MN, Hu SH, Zhang XW, Xiong SM, Deng H (2020) Overview on new progress of hereditary diffuse gastric cancer with CDH1 variants. Tumori 106(5):346–355

    Article  CAS  PubMed  Google Scholar 

  61. Corso G, Figueiredo J, De Angelis SP, Corso F, Girardi A, Pereira J et al (2020) E-cadherin deregulation in breast cancer. J Cell Mol Med 24(11):5930–5936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Huang R, Ding P, Yang F (2015) Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Drug Des Devel Ther 9:5277–5285

    CAS  PubMed  PubMed Central  Google Scholar 

  63. McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT (2015) Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res 17(1):12

    Article  PubMed  Google Scholar 

  64. Grellety T, Soubeyran I, Robert J, Bonnefoi H, Italiano A (2016) A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy. Ann Oncol 27(1):199–200

    Article  CAS  PubMed  Google Scholar 

  65. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70

    Article  CAS  Google Scholar 

  66. Krystel-Whittemore M, Wen HY (2022) Update on HER2 expression in breast cancer. Diagn Histopathol 28(3):170–175

    Article  Google Scholar 

  67. Corso G, Figueiredo J, La Vecchia C, Veronesi P, Pravettoni G, Macis D et al (2018) Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. J Med Genet 55(7):431–441

    Article  CAS  PubMed  Google Scholar 

  68. Corso G, Veronesi P, Sacchini V, Galimberti V (2018) Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur J Cancer Prev:27(3)

    Google Scholar 

  69. Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N et al (2021) Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist 26(6):e943–ee53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Karray-Chouayekh S, Trifa F, Khabir A, Sellami-Boudawara T, Frikha M, Gargouri A et al (2012) Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma. Histol Histopathol 27(3):377–385

    CAS  PubMed  Google Scholar 

  71. Corso G, Bonanni B, Veronesi P (2018) Tumor inactivation of E-cadherin: a new tool for breast cancer treatment? Ann Transl Med 6:S6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR et al (2013) Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 19(10):2668–2676

    Article  CAS  PubMed  Google Scholar 

  73. Padmanabhan N, Ushijima T, Tan P (2017) How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol 14(8):467–478

    Article  PubMed  Google Scholar 

  74. Yamazawa S, Ushiku T, Shinozaki-Ushiku A, Hayashi A, Iwasaki A, Abe H et al (2017) Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol 41(7):989–997

    Article  PubMed  Google Scholar 

  75. Comprehensive molecular characterization of gastric adenocarcinoma (2014) Nature 513(7517):202–209

    Article  Google Scholar 

  76. Katoh H, Ishikawa S (2017) Genomic pathobiology of gastric carcinoma. Pathol Int 67(2):63–71

    Article  PubMed  Google Scholar 

  77. Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L (2016) HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol 22(26):5879–5887

    Article  PubMed  PubMed Central  Google Scholar 

  78. Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476–484

    Article  PubMed  Google Scholar 

  79. Pandey I, Misra V, Pandey AT, Verma A (2022) Expression of HER2/neu in gastric adenocarcinoma and its correlation with serum HER2/neu level and E-cadherin expression. Indian J Pathol Microbiol 65(1):35–41

    PubMed  Google Scholar 

  80. Muzashvili T, Tutisani A, Chabradze G, Beridze N, Museridze N (2020) The study of the expression of CDH1, KI67, P53 and HER2 in diffuse gastric carcinoma. Georgian Med News 299:147–150

    Google Scholar 

  81. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396(10251):635–648

    Article  CAS  PubMed  Google Scholar 

  82. Iyer P, Moslim M, Farma JM, Denlinger CS (2020) Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. Transl Gastroenterol Hepatol 5:52

    Article  PubMed  PubMed Central  Google Scholar 

  83. De Re V, Alessandrini L, Brisotto G, Caggiari L, De Zorzi M, Casarotto M et al (2022) HER2-CDH1 interaction via Wnt/B-catenin is associated with patients’ survival in HER2-positive metastatic gastric adenocarcinoma. Cancers (Basel) 14(5)

    Google Scholar 

  84. Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM et al (2020) Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 21(8):e386–ee97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Wang J, Xiu J, Arai H, Battaglin F, Poorman K, Tokunaga R et al (2019) 679PD - large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC). Ann Oncol 30:v258

    Article  Google Scholar 

  86. Hemmerich A, Madison R, Klempner S, Sokol E, Severson E, Miller V et al (2019) O-006 - genomic profiling of diffuse gastric carcinoma (DGC). Ann Oncol 30:iv128

    Article  Google Scholar 

  87. Caggiari L, Miolo G, Buonadonna A, Basile D, Santeufemia DA, Cossu A et al (2017) Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype. Int J Mol Sci 19(1)

    Google Scholar 

  88. Fang C, Kang Y (2021) E-cadherin: context-dependent functions of a quintessential epithelial marker in metastasis. Cancer Res 81(23):5800–5802

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy

    Mariia Ivanova, Elham Sajjadi, Lorenzo Zattoni & Nicola Fusco

  2. Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy

    Elham Sajjadi, Lorenzo Zattoni & Nicola Fusco

Authors
  1. Mariia Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elham Sajjadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorenzo Zattoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Fusco .

Editor information

Editors and Affiliations

  1. European Institute of Oncology, University of Milan, Milan, Italy

    Giovanni Corso

  2. European Institute of Oncology, University of Milan, Milan, Italy

    Paolo Veronesi

  3. University of Siena, Siena, Italy

    Franco Roviello

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ivanova, M., Sajjadi, E., Zattoni, L., Fusco, N. (2023). HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations. In: Corso, G., Veronesi, P., Roviello, F. (eds) Hereditary Gastric and Breast Cancer Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-031-21317-5_10

Download citation

Publish with us

Policies and ethics

Search

Navigation